Vagifem

How to order Vagifem

1. Find the drug you need on our site.
2. Pick a clinic. See the price.
3. Fill in a short health form.
4. A doctor reads your form.
5. If it is safe for you, they say yes.
6. Your order ships fast to your door.
7. It comes in a plain, sealed box.

Why use us? We compare UK clinics. We show you the price and how fast they ship. We do not sell drugs. We just help you find the best one for you.

Is it safe? Yes. All our clinics are UK-based. A real doctor reads each form. They will not sell to you if it is not safe for you.

Vagifem on Prescriptsy

Vagifem is described on Prescriptsy as independent product information.

Here you can understand how online consultation works, what medical checks partner clinics carry out, and which factors matter when comparing providers.

We do not sell medicines directly, but help users compare licensed healthcare partners on price, delivery speed, service quality, and overall trustworthiness.

Vagifem is a low-dose vaginal oestrogen tablet containing 10 micrograms of estradiol, designed for the local treatment of vaginal atrophy (atrophic vaginitis) in postmenopausal women.

Each tablet is preloaded in a single-use applicator for hygienic and convenient insertion.

Vagifem works by delivering oestrogen directly to the vaginal epithelium, restoring tissue thickness, lubrication, elasticity, and the protective acidic pH that maintains urogenital health.

Because the dose is very low and acts locally, systemic absorption is minimal, and serum estradiol levels remain within the normal postmenopausal range throughout treatment.

Vaginal atrophy affects up to 50% of postmenopausal women, yet it remains significantly underdiagnosed and undertreated.

Many women are reluctant to discuss symptoms of vaginal dryness, discomfort, and painful intercourse, and may not realise that effective treatment is available.

Unlike vasomotor symptoms (hot flushes and night sweats), which tend to improve over time, vaginal atrophy is a progressive condition that worsens without treatment as oestrogen deficiency continues.

This page provides a comprehensive clinical overview of Vagifem, covering how it works, how to use it, its safety profile, and how to obtain a prescription in the UK.

Important safety information about Vagifem

Before reading further, note the following key safety points about Vagifem.

• Vagifem is a local vaginal treatment, not systemic HRT. It does not carry the same risk profile as oral or transdermal hormone replacement therapy.
• You do not need to take a progestogen alongside Vagifem at the 10 microgram dose, as endometrial stimulation is negligible.
• Report any vaginal bleeding to your prescriber for investigation, even if you are using vaginal oestrogen.
• Vagifem can be used for as long as symptoms persist. There is no arbitrary time limit on treatment with low-dose vaginal oestrogen.

Understanding vaginal atrophy

Vaginal atrophy, also known as atrophic vaginitis or genitourinary syndrome of menopause (GSM), is a chronic progressive condition caused by the decline in circulating oestrogen levels after the menopause.

Oestrogen plays a critical role in maintaining the structure and function of the vaginal and lower urinary tract tissues.

When oestrogen levels fall, the vaginal epithelium thins from a robust stratified squamous epithelium to a fragile, easily traumatised layer with reduced glycogen stores.

Lactobacillus colonisation declines, vaginal pH rises from the normal acidic range (3.5 to 4.5) to a more alkaline level (5.0 to 7.0), and the vaginal environment becomes susceptible to colonisation by uropathogenic and other non-lactobacillus organisms.

The clinical consequences include vaginal dryness, burning, itching, and soreness; narrowing and shortening of the vagina; loss of rugae (the normal folds of the vaginal wall); dyspareunia (pain during sexual intercourse); post-coital bleeding; recurrent urinary tract infections (UTIs); urinary urgency and frequency; and dysuria.

These symptoms can profoundly affect quality of life, sexual function, and intimate relationships.

Unlike hot flushes, which typically diminish within 5 to 10 years, vaginal atrophy does not resolve spontaneously and tends to worsen progressively if untreated.

Prevalence in the UK

Studies suggest that 40 to 55% of postmenopausal women experience symptoms of vaginal atrophy, but fewer than 25% seek medical help.

A survey by the British Menopause Society found that many women were unaware that vaginal dryness was related to menopause and that effective prescription treatments existed.

GPs and practice nurses play a vital role in proactively asking about urogenital symptoms during menopause consultations, as patients may not volunteer these complaints.

How Vagifem works

Local oestrogen restoration

Vagifem delivers 10 micrograms of estradiol (as estradiol hemihydrate) directly to the vaginal mucosa via a small bioadhesive tablet.

Once the tablet dissolves and estradiol is absorbed into the vaginal epithelial cells, it binds to oestrogen receptors (ER-alpha and ER-beta) and initiates a cascade of cellular responses.

The superficial and intermediate layers of the vaginal squamous epithelium proliferate and mature, increasing mucosal thickness and resistance to mechanical trauma.

Glycogen stores are replenished, providing the substrate for Lactobacillus metabolism, which produces lactic acid and restores the protective acidic vaginal pH.

Submucosal blood flow increases, enhancing vaginal lubrication and tissue health.

These restorative effects begin within the first 2 weeks of daily treatment and continue to improve over 3 to 12 months of maintenance therapy.

Objective measures of improvement include increased vaginal maturation index (reflecting a higher proportion of superficial epithelial cells on cytology), decreased vaginal pH, and increased vaginal moisture as measured by clinical assessment or patient-reported outcome tools.

Minimal systemic absorption

The 10 microgram Vagifem formulation was specifically developed to minimise systemic oestrogen exposure while maintaining full local efficacy.

Pharmacokinetic studies have demonstrated that serum estradiol levels during Vagifem use remain within the normal postmenopausal range (below 20 picograms per millilitre).

This is in contrast to systemic HRT preparations, which raise serum estradiol to premenopausal or perimenopausal levels.

The minimal systemic exposure means that Vagifem does not carry the same risks of venous thromboembolism, breast cancer, or stroke associated with oral or transdermal HRT, and does not require the addition of a progestogen for endometrial protection in the vast majority of women.

Clinical evidence and national guidelines

Vagifem 10 micrograms has been evaluated in multiple randomised controlled trials demonstrating significant improvement in vaginal atrophy symptoms compared with placebo.

The pivotal trials showed statistically significant improvement in the vaginal maturation index, vaginal pH, and patient-reported severity of the most bothersome symptom (typically dryness or dyspareunia) from as early as week 2, with sustained benefit over 12 months of treatment.

Endometrial safety was assessed in dedicated studies where endometrial biopsies were performed after 52 weeks of Vagifem 10 microgram use.

No cases of endometrial hyperplasia or carcinoma were detected, confirming that the 10 microgram dose does not significantly stimulate the endometrium.

This evidence supports the recommendation that progestogen co-prescription is not required.

NICE Guideline NG23 recommends vaginal oestrogen as the first-line treatment for vaginal atrophy symptoms that do not respond to non-hormonal lubricants and moisturisers.

The guideline states that vaginal oestrogen can be offered to women with a history of breast cancer who have tried non-hormonal options without adequate relief, following discussion with their oncologist.

NICE also notes that local vaginal oestrogen can be continued for as long as it is needed, without the durational limitations that apply to systemic HRT.

The British Menopause Society and the International Menopause Society both endorse these recommendations.

Who is Vagifem suitable for

Vagifem is suitable for postmenopausal women experiencing symptoms of vaginal atrophy, including vaginal dryness, soreness, itching, dyspareunia, and recurrent urinary tract infections related to urogenital oestrogen deficiency.

It may be used as a standalone treatment in women whose menopausal symptoms are limited to the urogenital tract, or in combination with systemic HRT in women who have persistent vaginal symptoms despite adequate systemic oestrogen replacement.

Vagifem may also be considered for women with premature ovarian insufficiency (menopause before age 40) or surgical menopause who experience vaginal atrophy.

Women using aromatase inhibitors for breast cancer treatment are particularly susceptible to severe vaginal atrophy; the decision to use vaginal oestrogen in this context should involve the oncology team.

How to use Vagifem

Vagifem is supplied in a calendar pack containing individual applicators, each preloaded with one estradiol 10 microgram vaginal tablet. The applicator is designed for single use and should be discarded after each insertion.

Insertion technique

Lie down or stand with one foot raised on a chair or the edge of a bath, whichever position is most comfortable.

Remove the applicator from its blister pack. Hold the applicator by the thick end (the plunger end) with the thin tablet end pointing upward or away from you.

Gently insert the thin end into the vagina as far as is comfortable, typically about 8 centimetres. Press the plunger firmly to release the tablet.

The tablet will adhere to the vaginal wall. Withdraw the applicator gently and dispose of it in household waste. Wash your hands after use.

Dosing schedule

During the first 2 weeks: Insert one tablet daily, at approximately the same time each day (bedtime is often convenient).

From week 3 onwards: Insert one tablet twice weekly, with at least 3 days between insertions (for example, Monday and Thursday).

Continue this maintenance schedule for as long as symptoms persist, with annual review by your prescriber.

Practical tips

Insert the tablet at bedtime to allow it to dissolve while you are lying down, which maximises contact time with the vaginal mucosa.

The tablet is small and is retained within the vagina; it does not need to be in a precise position to work.

If you experience initial discomfort during insertion, applying a small amount of water-based lubricant to the tip of the applicator may help.

Do not use Vagifem as a lubricant; if additional lubrication is needed during intercourse, use a water-based or silicone-based personal lubricant.

Side effects of Vagifem

Common local effects

Vaginal discomfort, burning, or itching at the insertion site may occur during the first few days of treatment, particularly in women with severe atrophy where the vaginal mucosa is very thin and fragile.

These symptoms typically resolve as the vaginal epithelium thickens and regenerates in response to oestrogen.

Vaginal discharge (white or clear) is common and reflects increased vaginal secretions, which is a sign that the treatment is working.

Mild vaginal bleeding or spotting may occur during the initial loading phase and should resolve; if bleeding persists or recurs, inform your prescriber.

Uncommon systemic effects

At the 10 microgram dose, systemic side effects are uncommon because serum estradiol levels remain within the postmenopausal range.

Headache, nausea, and abdominal pain have been reported occasionally but are not consistently attributed to Vagifem in clinical trials.

Breast tenderness is not typically associated with this low-dose local formulation.

Rare but important effects

Hypersensitivity reactions (local rash, swelling, or urticaria) are rare.

Endometrial stimulation at the 10 microgram dose has not been demonstrated in clinical studies of up to 52 weeks' duration, but any vaginal bleeding should prompt endometrial investigation.

The theoretical systemic risks of oestrogen therapy (VTE, breast cancer, stroke, endometrial cancer) are not considered to be increased with low-dose vaginal oestrogen, as confirmed by NICE NG23 and the BMS.

When to seek medical advice

Consult your GP or NHS 111 if you experience persistent or heavy vaginal bleeding, worsening vaginal symptoms despite treatment, persistent abdominal pain, or any signs of allergic reaction.

Report any suspected adverse reactions via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk .

Warnings and precautions

Contraindications

Vagifem is contraindicated in women with known or suspected breast cancer, known or suspected oestrogen-dependent malignancy, undiagnosed vaginal bleeding, untreated endometrial hyperplasia, active or previous VTE (DVT, PE), active arterial thromboembolic disease (stroke, MI), acute liver disease, or hypersensitivity to estradiol or any excipient.

As noted above, in clinical practice many of these contraindications are applied with less rigidity for low-dose vaginal oestrogen than for systemic HRT, given the negligible systemic absorption, but prescribers should document their clinical reasoning.

Vaginal bleeding

Any vaginal bleeding during treatment with Vagifem should be investigated, as it may indicate endometrial pathology unrelated to the vaginal oestrogen.

Investigation typically involves transvaginal ultrasound to measure endometrial thickness, with endometrial biopsy if the thickness is above the normal postmenopausal threshold or if bleeding persists.

Breast cancer considerations

The SmPC lists breast cancer as a contraindication.

However, NICE NG23 states that vaginal oestrogen can be considered for women with a history of breast cancer who have not responded to non-hormonal treatments (lubricants, moisturisers), after discussion with their oncologist or breast cancer specialist.

The minimal systemic absorption at the 10 microgram dose is the basis for this clinical recommendation.

Women on aromatase inhibitors should seek specialist advice, as even small amounts of absorbed oestrogen may theoretically counteract the aromatase inhibitor effect.

Use with systemic HRT

Some women on systemic HRT (tablets, patches, or gel) may still experience vaginal atrophy symptoms. In these cases, Vagifem can be used concurrently.

The progestogen component of systemic HRT provides endometrial protection; no additional progestogen is needed for the vaginal oestrogen.

Non-hormonal alternatives

For women who prefer not to use hormonal treatments, or for whom Vagifem is contraindicated, non-hormonal options include vaginal moisturisers (such as Replens, used regularly to maintain vaginal hydration) and water-based or silicone-based personal lubricants (used during sexual activity).

While these products provide symptomatic relief, they do not reverse the underlying epithelial changes of vaginal atrophy. NICE recommends offering vaginal oestrogen when non-hormonal measures are insufficient.

How to obtain Vagifem in the UK

Vagifem is a prescription-only medicine (POM).

It can be prescribed by your GP, a menopause specialist, a gynaecologist, or an authorised online prescriber registered with the GPhC and CQC.

A brief clinical assessment is required, which may include a symptom history and, if appropriate, vaginal examination. No blood tests are typically needed before starting low-dose vaginal oestrogen.

Vagifem is available from all UK pharmacies.

The standard NHS prescription charge in England is currently 9.90 pounds per item; prescriptions are free in Scotland, Wales, and Northern Ireland.

Living with vaginal atrophy: practical guidance

Vaginal atrophy is a long-term condition that requires ongoing management. In addition to using Vagifem as prescribed, the following measures can help maintain vaginal and urogenital health.

Continue to use Vagifem for as long as symptoms persist; stopping treatment will result in a return of symptoms as the oestrogen-deprived tissues revert to their atrophic state.

Use a non-hormonal vaginal moisturiser regularly (every 2 to 3 days) alongside Vagifem for additional comfort, particularly during the initial treatment phase.

Use a water-based or silicone-based lubricant during sexual activity to reduce friction and discomfort.

Avoid perfumed soaps, bubble baths, vaginal douches, and deodorants in the genital area, as these can further irritate atrophic tissues.

Wear cotton underwear and avoid tight clothing that traps moisture.

Regular sexual activity (with or without a partner) helps maintain vaginal blood flow, elasticity, and natural lubrication.

If dyspareunia has been a barrier to intimacy, starting Vagifem can gradually restore comfort and confidence.

Open communication with your partner and, if needed, psychosexual counselling can be valuable components of managing the impact of vaginal atrophy on your relationship and wellbeing.

When to seek urgent medical advice

Contact your GP or NHS 111 if you experience persistent or unexplained vaginal bleeding, worsening symptoms despite treatment, or signs of vaginal infection (unusual discharge, odour, or pain).

Seek emergency medical advice (call 999 or attend A&E) if you develop symptoms of a serious allergic reaction, sudden chest pain or breathlessness, or painful leg swelling.

Report any suspected adverse reactions to Vagifem via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk .

Sources

• Vagifem 10 micrograms Vaginal Tablets, Summary of Product Characteristics (EMC)
• Estradiol, British National Formulary (BNF)
• NICE NG23: Menopause: diagnosis and management
• Menopause, NICE CKS
• British Menopause Society
• Vaginal Dryness, NHS
• MHRA Yellow Card Scheme